Browsing by Author "Yalçin, P"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Prevalence of Rheumatoid Arthritis and Spondyloarthritis in Turkey: A Nationwide Study
    (TURKISH LEAGUE AGAINST RHEUMATISM) Tuncer, T; Gilgil, E; Kaçar, C; Kurtais, Y; Kutlay, S; Bütün, B; Yalçin, P; Akarirmak, Ü; Altan, L; Ardiç, F; Ardiçoglu, Ö; Altay, Z; Cantürk, F; Cerrahoglu, L; Çevik, R; Demir, H; Durmaz, B; Dursun, N; Duruöz, T; Erdogan, C; Evcik, D; Gürsoy, S; Hizmetli, S; Kaptanoglu, E; Kayhan, Ö; Kirnap, M; Kokino, S; Kozanoglu, E; Kuran, B; Nas, K; Öncel, S; Sindel, D; Orkun, S; Sarpel, T; Savas, S; Sendur, OF; Senel, K; Ugurlu, H; Uzunca, K; Tekeoglu, I; Guillemin, F
    Objectives: This study aims to estimate the prevalence of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in Turkey using the same telephone questionnaire developed for screening RA and SpA in France and used in Serbia and Lithuania. Material and methods: The study was performed in two steps. In step I, the French questionnaire was translated into Turkish and validated through a group of 200 patients (80 males, 120 females; mean age 44.0 +/- 13.1 years; range, 19 to 75 years) followed up at the rheumatology departments of University Hospitals in Antalya and Ankara. In step II, the validated Turkish questionnaire was administered face-to-face to randomly selected 4,012 subjects (1,670 males, 2,342 females; mean age 41.5 +/- 16.8 years; range, 16 to 97 years) by trained general practitioners across the country, in 25 provinces for case detection. The subjects who were suspected of having RA or SpA in accordance with the questionnaire were invited to the nearest university hospital for rheumatologic examination in order to confirm the diagnosis. Results: In step II, a total of 25 subjects (2 males, 23 females) were diagnosed as RA. The standardized RA prevalence for the general population of Turkey was calculated as 0.56% (95% confidence interval [CI]; 0.33-0.79), 0.10% (95% CI; -0.05-0.25) for males and 0.89% (95% CI; 0.51-1.27) for females. A total of 18 subjects (3 males, 15 females) were diagnosed as SpA. The standardized SpA prevalence for the general population of Turkey was 0.46% (95% CI; 0.25-0.67), 0.17% (95% CI; -0.03-0.37) for males and 0.65% (95% CI; 0.32-0.98) for females. The prevalence of RA was highest in the Northern region (2.00%) and the prevalence of SpA was highest in the Central region (1.49%). Conclusion: The prevalences of RA and SpA in Turkey are close to each other and there are significant inter-regional variations in prevalences of both RA and SpA.
  • No Thumbnail Available
    Item
    Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR
    (TURKISH LEAGUE AGAINST RHEUMATISM) Ataman, S; Sürmeli, ZS; Sunar, I; Özdemirel, E; Akinci, A; Bodur, H; Akgül, Ö; Altan, L; Altay, Z; Ayhan, F; Birtane, M; Soy Bugdayci, D; Çapkin, E; Cerrahoglu, L; Duruöz, MT; Günaydin, R; Günendi, Z; Gürer, G; Bal, A; Kaçar, C; Kaptanoglu, E; Kaya, T; Kocabas, H; Kotevoglu, N; Nas, K; Rezvani, A; Sen, N; Sendur, OF; Yalçin, P
    Objectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey. Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected. Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same. Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.
  • No Thumbnail Available
    Item
    Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study
    (GALENOS YAYINCILIK) Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardiç, F; Bütün, B; Akyüz, G; Cerrahoglu, L; Sendur, ÖF; Yalçin, P; Öncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gürsoy, S; Cantürk, F; Demir, H; Özdener, F; Öncel, H
    Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7 +/- 9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered YES to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3 +/- 17.7 points), quality of life (10.4 +/- 20.4 points), overall satisfaction (11.9 +/- 22.7 points), and side effects (3.3 +/- 18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (>= 80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012; 18: 1-7)